key: cord-0913701-scwowzla
authors: Gaajetaan, Giel R.; Bruggeman, Cathrien A.; Stassen, Frank R
title: The type I interferon response during viral infections: a “SWOT” analysis
date: 2011-10-03
journal: Rev Med Virol
DOI: 10.1002/rmv.713
sha: 5530c38178ec0cf33b020c79f7461e46e7cb3818
doc_id: 913701
cord_uid: scwowzla

The type I interferon (IFN) response is a strong and crucial moderator for the control of viral infections. The strength of this system is illustrated by the fact that, despite some temporary discomfort like a common cold or diarrhea, most viral infections will not cause major harm to the healthy immunocompetent host. To achieve this, the immune system is equipped with a wide array of pattern recognition receptors and the subsequent coordinated type I IFN response orchestrated by plasmacytoid dendritic cells (pDCs) and conventional dendritic cells (cDCs). The production of type I IFN subtypes by dendritic cells (DCs), but also other cells is crucial for the execution of many antiviral processes. Despite this coordinated response, morbidity and mortality are still common in viral disease due to the ability of viruses to exploit the weaknesses of the immune system. Viruses successfully evade immunity and infection can result in aberrant immune responses. However, these weaknesses also open opportunities for improvement via clinical interventions as can be seen in current vaccination and antiviral treatment programs. The application of IFNs, Toll‐like receptor ligands, DCs, and antiviral proteins is now being investigated to further limit viral infections. Unfortunately, a common threat during stimulation of immunity is the possible initiation or aggravation of autoimmunity. Also the translation from animal models to the human situation remains difficult. With a Strengths–Weaknesses–Opportunities–Threats (“SWOT”) analysis, we discuss the interaction between host and virus as well as (future) therapeutic options, related to the type I IFN system. Copyright © 2011 John Wiley & Sons, Ltd.

For centuries, infectious diseases have been the most common cause of morbidity and mortality worldwide. Due to achievements like vaccination and antimicrobial drugs, many infectious diseases can now be prevented or controlled. Most striking in this respect is the development of a vaccine against smallpox, a lethal virus that globally claimed millions of lives. Although the vaccination procedure was already developed in the 18th century, it lasted until the end of the 20th century before the world was declared smallpox-free. Based on this success, there was great confidence that viral infections could be conquered definitely, either by vaccination or by antiviral drug treatment. Inspired by these successes, the US Surgeon General William Stewart stated in 1967 that "The time has come to close the book on infectious diseases". Unfortunately, the future has shown otherwise.

In 1983, the HIV was discovered as the AIDS causing agent. Despite massive efforts, HIV is still a major problem worldwide [1, 2] . In addition, the rise of new (variants of) viruses like influenza A strains [3, 4] and severe acute respiratory syndrome corona virus (SARS CoV) and their potential pandemic threat is a general and realistic concern [5] . Furthermore, seasonal respiratory viral infections and various other viruses can cause major inconvenience in healthy people and can be life-threatening in the immunocompromised [5, 6] . Thus, despite vaccines and antiviral drugs, viral disease is still common and requires development of additional therapeutics.

In this review, we apply a Strengths-Weaknesses-Opportunities-Threats (SWOT) analysis to discuss virus-immune interactions and speculate on (im) possibilities how to use these interactions in view of new treatment options.

Once the virus has been able to cross first barriers like the skin or mucosa, the strength of the host's natural defense system will determine the outcome of the infection. In the succeeding text, we will briefly discuss some of the initial key steps involved in the antiviral response (see also Figure 1 ).

Before an appropriate immune response can be generated, the virus needs to be recognized. For this, immune cells are equipped with different groups of receptors, which are able to sense microbial intruders including viruses. These pattern recognition receptors (PRRs) recognize pathogenassociated molecular patterns (PAMPs), which are fundamentally different from host structures. One of the first discovered and best characterized PRRs are the Toll-like receptors (TLRs) [7-10], which are mostly present on antigen-presenting cells like macrophages and dendritic cells (DCs) [8, 9] , but also on non-immune cells like fibroblasts and epithelial cells [10] . These transmembrane receptors are located on the cell surface or at the endosome [7, [9] [10] [11] . The cell surface-located TLRs recognize mainly lipids and proteins from bacteria and yeasts [10] . Viruses, on the other hand, are intracellular parasites, which Figure 1 . Schematic overview of different signal transduction pathways that are activated in plasmacytoid dendritic cells (pDCs) and conventional dendritic cell (cDCs) following viral encounters. In general, pDCs endocytose the virus and subsequently Toll-like receptor 7 (TLR7) and/or TLR9 is stimulated. Interferon response factor 7 (IRF7) is activated and induces transcription of IFNa/b. Besides execution of many antiviral functions, autocrine signaling via the interferon a/b receptor (IFNAR) also induces more type I IFN production. In contrast, infection of or endocytosis by cDCs results in activation of the cytoplasmic pattern recognition receptors, TLR3, and TLR8. Accordingly, IRF3 and nuclear factor-kB (NF-kB) facilitate transcription of IFNb and proinflammatory cytokines. Via IFNAR, IRF7 is activated and induces production of type IFNa/b. Red indicates major routes, dotted arrows indicate minor routes may explain the endosomal localization of the viral nucleic acid-recognizing TLR3, TLR7, TLR8, and TLR9 ( Figure 1 ) [11] [12] [13] [14] [15] [16] [17] [18] [19] . Also, this endosomal location of the TLRs probably serves to ensure tolerance for "self" molecules and to promote ligand accessibility [10, 14] . Interestingly, in addition to the well-known lipopolysaccharides from Gram-negative bacteria, cell surface TLRs have also been associated with viral recognition. TLR4 has been shown to recognize the fusion protein of RSV [10, 20] . Likewise, next to the recognition of Gram-positive bacteria, TLR2 is involved in detection of various DNA viruses like HSV1 and 2, measles virus, vaccinia virus, and CMV [21] [22] [23] . Interstingly, this TLR2-dependent detection seems to be regulated especially by monocytes [21, 22, 24] .

In addition to the well-described TLRs, other PRRs also play an important role in viral recognition. The cytoplasmic PRRs, such as retinoic acidinducible gene I (RIG-I), melanoma differentiationassociated gene 5 (MDA5), and DNA-dependent activator of IFN-regulatory factors (DAI), recognize viral nucleic acids [25, 26] and are, in contrast to TLRs, expressed in all cells. RNA viruses are differentially recognized by RIG-I and MDA5, but activate similar pathways ( Figure 1) Taken together, the innate immune system is equipped with a large variety of PRRs and this extended array is essential to sense the various microbial components and to prevent or limit viral spread as much as possible [7,44,45].

Implementation of antiviral immunity: conventional and plasmacytoid dendritic cells After recognition of a virus, a cell-dependent signaling cascade will be initiated. Infection of non-immune cells usually results in detection of viral DNA/RNA or their intermediates by the cytoplasmic PRRs and the production of IFNb, which is required to limit the infection. This antiviral cytokine also primes cells to produce other type I IFNs, which comprise all IFNa subtypes, IFNb, and various other IFN types, essential to initiate production of antiviral proteins [46] .

Dendritic cells are better equipped than nonimmune cells for the initiation of an antiviral response. Conventional dendritic cells (cDCs) recognize viral invaders with both extracellular (TLR 4 and CLRs) and intracellular PRR (TLR3, 8, RIG-I, MDA5), which are highly expressed on cDCs ( Figure 1 ) [11, 12, 47, 48] . As in infection of nonimmune cells, viral nucleic acids need to be detected before IFNb and other type I IFNs can be produced.

For the successful eradication or control of the virus, the intervention of plasmacytoid dendritic cells (pDCs) is indispensable. The pDC is one of the few cells that express both TLR7 and TLR9 (Figure 1 ), allowing detection of an extended repertoire of viruses. To initiate the antiviral response, viruses or virus-infected cells are first internalized by endocytosis or phagocytosis, respectively, and subsequently recruited to the endolysosomes of the pDC [49] . The acidic environment disassembles the virus, and viral nucleic acids are subsequently recognized by TLR7 or TLR9 [50,51]. Ultimately, massive amounts of type I IFN are produced. In contrast to cDCs and non-immune cells, in pDCs the TLRs contribute significantly more to viral recognition than the cytoplasmic PRRs RIG-I and MDA5 [26, 52, 53] . Consequently, pDCs are less dependent on steps in the viral life cycle for recognition, which significantly accelerates the response to an infection in these DCs.

The difference in response time between pDC and cDC is also because of marked differences in intracellular signaling cascades that are activated following PRR stimulation. In cDCs, viral components stimulate the TLRs (apart from the cytoplasmic PRRs) resulting in phosphorylation of interferonregulatory factor 3 (IRF3). IRF3 is essential for the production of proinflammatory cytokines and IFNb (the first wave IFN) and is constitutively expressed, not only in cDCs but in most cell types [10,54]. Next, because of autocrine or paracrine signaling through the interferon-a/b receptor (IFNAR), IRF7 is activated, leading to the production of all type I IFNs including the various IFNa subtypes (the second wave IFN) [55, 56] . Alternatively, in pDCs IRF7 is constitutively expressed and activated immediately after stimulation of TLR7 or TLR9, and thus no prior phosphorylation of IRF3 or autocrine/paracrine signaling is required ( Figure 1) [48,52,57-60]. Accordingly, a robust antiviral response is initiated that, in contrast to the response seen in cDCs, is rapid and characterized by the production of high amounts of type I IFNs [61, 62] .

Consequently, the pDC is clearly the major antiviral cell type due to its rapid and abundant IFNa production. Yet, the cDC is indispensable for clearance of a viral infection. This can be illustrated by the function of TLR8 expressed by cDCs. This receptor is similar to TLR7 in pDCs and also recognizes viral ssRNA. Interestingly, stimulation of TLR8 on cDCs and TLR7 on pDCs results in entirely different responses [63] . Although the pDC produces mainly IFNa, the cDC induces a pro-inflammatory profile in which nuclear factor-kB (NF-kB) is activated for the production of TNF-a and IL-6 [64]. More importantly, IL-12 is produced ( Figure 1 ). This cytokine augments the cytolytic activity of natural killer (NK) cells and also induces the production of the immunoregulatory cytokine IFNg by T and NK cells [65] . Thus, although both DC subsets use different antiviral pathways, they are certainly not mutually exclusive in their response to viral infection. Because of their different cytokine patterns, pDCs and cDCs respond collaboratively to viral infection and connect innate and adaptive immunity [66] . Communication and cooperation between these two DC subsets are vital to induce appropriate immune responses towards invading pathogens.

The type I IFNs are key effector molecules of the innate immune system and are essential for the antiviral response towards a plethora of viruses. In humans, the type I IFN family comprises 13 IFNa subtypes, IFNb, IFNk, IFNe, IFNο, IFNt, and IFNd, and all these molecules engage the ubiquitously expressed IFNAR. Binding to IFNAR then stimulates more than 300 interferon-stimulated genes (ISGs) [67, 68] , which subsequently induce an antiviral state. The antiviral state is a collective term for limitation of viral replication, viral resistance of neighboring cells, and apoptosis of virally infected cells.

Although IFNAR signaling induces the transcription of more than 300 ISGs, surprisingly, few of these genes encode proteins with direct antiviral effects [69] . Those proteins target viruses in many different ways ( Figure 1 Interferons also induce antiviral proteins termed restriction factors. A good example is the bone marrow stromal antigen-2 (BST-2) protein, which restricts the release of fully formed progeny virions from infected cells. This tetherin protein showed activity against various viruses, including HIV [78] [79] [80] . Another restriction factor is apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), which leads to degradation of HIV DNA [81,82]. The restriction factor tripartite motif (TRIM) 5a seems to counteract capsid formation by HIV (reviewed by Sastri et al.) [83] .

In addition, many proteins stimulated by type I IFN are involved in IFN signaling (IRF7, RIG-I, MDA5, TLRs), thereby amplifying the IFN response (positive feedback). IFNs also induce or modulate adaptive immune responses by upregulating MHC class I and II, to facilitate T and B cell stimulation [84, 85] . Finally, IFNs promote leukocyte accumulation at sites of infection by promoting vascular adhesion molecule expression and induction of chemokines, which are essential in leukocyte recruitment [86] .

Recently, a new type I IFN-dependent antiviral pathway has been suggested. Pedersen et al. demonstrated that IFNb rapidly induced the expression of several microRNAs (miRNAs) both in a hepatocarcinoma cell line (Huh cells) and primary hepatocytes [87] . These small non-coding RNA molecules are post-transcriptional regulators that inhibit gene expression by translational repression, mRNA cleavage and deadenylation [87, 88] . Intriguingly, eight of these IFNb-induced miRNAs showed sequence-predicted targets within the HCV genomic RNA. Moreover, application of synthetic miRNAmimics resulted in antiviral effects similar to those induced by IFNb, whereas anti-miRNA markedly reduced the IFNb-mediated antiviral effect [87] . In addition, it has recently been shown that hepatic miRNA expression might be a useful tool for predicting the therapeutic outcome of a pegylated IFN/ ribavirin combination therapy, further emphasizing the potential role of miRNAs in IFN-mediated antiviral effects [89] .

In conclusion, the presence of a wide variety of PRRs enables the detection of multiple viral ligands present during infection. Activation of the PRR-DC-type I IFN axis (and especially the TLR7/9-pDC-IFNa axis) induces a rapid response to the virus. The many ISGs and the diversity of the type I IFNs that can be stimulated or produced, respectively, enables a coordinated response to the various viral infections, leading to control or elimination of the viral intruder.

In the previous section, we described how wellequipped the immune system is to protect the host against viral infections. Nevertheless, viruses can evade or influence the immune response by targeting certain weaknesses of the immune system resulting in (severe) disease.

Because of the strong antiviral and immunoregulatory role of type I IFN, viruses developed a large variety of anti-type I IFN mechanisms. Consequently, nearly all steps of the type I IFN pathway can be blocked or manipulated by different viruses for their own benefit ( Alternatively, virus-related morbidity and mortality are not only due to virus-induced immune evasion, which facilitates extensive viral replication, but may also result from a concomitant, an inappropriate, and an exaggerated response of [6] . Thus, the increased resistance to the antiviral effects of IFN enhances viral replication and evokes an aberrant proinflammatory response characterized by high levels of cytokines and chemokines, which induces the pulmonary injury observed in H5N1 patients. Likewise, the devastating effects of an HIV infection may also results from such a combination. HIV infection results in progressive immune deficiency, impaired adaptive responses, low CD4 T cell counts and increases susceptibility to opportunistic infections. One of the earliest findings during the AIDS epidemic was a deficient IFNa production in HIVinfected patients. Next to a lower number of IFNproducing cells, also each cell produced less IFNa in response to HIV [113, 114] . The decrease in IFNa can be due to the Vpr protein of HIV, which strongly inhibits type I IFN production by pDCs [115] . In addition, the effects of IFNa are antagonized by the HIV protein Vpu, which induces degradation of the restriction factor BST2 [79,116]. However, during the chronic phase of HIV infection, it is hypothesized that IFNa contributes to the decline of the immune system by inducing apoptosis of CD4 T cells. Because of the non-infectious interaction between the HIV-bound gp120 protein and the CD4 receptor on pDCs, IFNa is produced and this results in killing (possibly by pDCs) of uninfected CD4 T cells [114] [115] [116] [117] . Thus, although apoptosis of infected cells is usually a protective mechanism to prevent viral spread [118,119], here, it results in a distinct advantage for the virus due to the decreased immune control by CD4 T cells.

Thus, despite the strength of the type I IFN system, viruses have evolved mechanisms to evade or manipulate the system to guarantee their survival. Among others, this is predominantly accomplished through interfering with PRR signaling, inhibition of IRF3 and IRF7 activation and targeting ISGs.

The search for therapies has led to the development of vaccines and antiviral drugs, which resulted in an impressive reduction in virus-related morbidity and mortality. Unfortunately, both vaccination and antiviral drugs are not sufficient to prevent or control all viral infections, which make it imperative to develop novel therapies. As a result, immune-based therapies are currently under development as new treatment methods. This may provide new opportunities for the treatment of acute or chronic viral infections ( Figure 2 ). 

A plausible approach to treat virally infected patients is the administration of type I IFN. Indeed, pegylated IFNa in combination with the antiviral drug ribavirin is commonly used in treating patients with a chronic HCV infection. Although this therapy is effective in nearly 50% of the cases, the administration of pegylated IFNa is associated with severe side effects [120 -122] . Normally, during viral infections, type I IFN gives the "sicksignal" that results in fever. Patients treated with type I IFN have to endure these feverish periods for prolonged periods of time. In addition, hematologic and psychological problems have been frequently reported during treatment periods. Also with respect to HIV, positive effects of IFN-treatment have been reported both in vitro [123, 124] , as in clinical trials [125] [126] [127] [128] [129] . On the other hand, (excessive) IFNa can contribute to the immunopathogenesis (reviewed by Herbeuval et al.) [117] . Thus, it remains controversial whether IFNa is beneficial or detrimental in HIV, because both underproduction and overproduction of IFNa can induce severe effects in the host.

Nonetheless, because of their strong antiviral effects, type I IFNs remain attractive drugs for antiviral therapy. In particular during acute (respiratory) infections, IFNs may be an interesting therapy. This requires no systemic and chronic application of IFNs as observed in HCV patients, which may, therefore, significantly reduce the observed side effects. Local application, for example, by a nasal spray, has been shown to be effective in the prevention of seasonal respiratory infections without causing severe side effects [86, 130] . This administration route might be, particularly, attractive for the prevention of virus-induced exacerbations in chronic obstructive pulmonary disease and asthmatic patients in which impaired IFN production may be an important mechanism contributing to virus-induced exacerbations [131, 132] . IFNa also showed promising effects in severe acute respiratory syndrome (SARS) [133] [134] [135] and can be very important to induce an adequate immune response and possibly suppress excessive inflammatory responses observed in SARS [136] [137] [138] [139] . Interestingly, also other members of the IFN family can be used to prevent or treat viral respiratory infections. The recently discovered type III IFNs (or IFNl1 and IFNl2/3) show strong antiviral effects against respiratory viral infections [131, [140] [141] [142] , especially when given prophylactically [142, 143] .

Because stimulation of TLRs by antigenic microbial epitopes is sufficient to induce a full-blown immune response, TLRs seem a likely target for antimicrobial therapy. Indeed, synthetic variants of the microbial structures have been shown to induce natural responses without the need for infection, and this quality has been used extensively to improve the efficacy of vaccines. For example, vaccines composed of a mixture of TLR ligand and antigens have been shown to be more effective than antigens alone [144] [145] [146] [147] [148] . Moreover, TLR ligands covalently linked to peptides are even superior in their ability to induce specific CD8+ T cells [149] .

When a direct antiviral response is required, the use of synthetic TLR3, TLR7, TLR8, or TLR9 ligands can be considered. Both in vitro and in vivo studies have shown that prophylactic treatment with the dsRNA mimic polyinosinic:polycytidylic acid (poly (I:C)) and CpG oligodeoxynucleotides (CpG ODNs) specific for TLR3 and TLR9, respectively, is protective during viral infection [150] [151] [152] [153] . Depending on virus and cell type, different types of CpG ODNs can be applied to initiate an appropriate response [154] [155] [156] . Also, TLR7 and TLR8 may be therapeutic targets. For stimulation of these TLRs, imidazoquinolones (e.g. resiquimod and imiquimod) are the best known ligands, and these small molecular weight compounds have indeed been shown to possess antiviral properties [15, 16, [157] [158] [159] [160] , although their immunostimulatory and antiviral effect may be limited compared with poly (I:C) and CpG ODNs [161] . Interestingly, the use of imiquimod as a cream to treat human papillomavirus-induced genital warts has already been approved [16, 145, 162] . TLR ligands can also reduce HCV viremia [163] [164] [165] and even HIV could be targeted [166] . Besides stimulation of type I IFN production, TLR ligands also initiate immunoregulatory mechanisms [167] . This is particularly important for the generation of the adaptive immune response and immunological memory. Nonetheless, at this time, few TLR ligands have been approved for clinical application in treating viral disease [13, 148] .

During various viral infections, pDCs (and cDCs) are less functional or are present in lower numbers [168] [169] [170] . This is, for example, observed in HCVinfected [171, 172] and HIV-infected patients, where the number of pDCs (partially) predicts the clinical outcome [173] [174] [175] . Therefore, adoptive transfer of pDCs (and cDCs) can be used to reach the required level of pDCs and the subsequent initiation of the type I IFN response. Moreover, this will increase the efficacy of TLR ligands as they require their appropriate receptors that are predominantly present on DCs. As shown by Wang et al., adoptive transfer of pDCs was used to successfully activate the antiviral response and limit RSV replication [176] . Thus, the administration of (stimulated) pDCs (in concert with cDCs) to restore DC function and/or numbers can activate the innate immune system to reach the required level of immune activation to control the viral infection, but this is probably dependent on the individual, the type of viral infection (chronic) and the stage of infection.

As observed in many viral infections, the (concomitant) proinflammatory response can contribute significantly to the disease. Therefore, anti-inflammatory drugs [177] are attractive to suppress symptoms during viral disease. Also, the use of antiviral drugs for specific inhibition of viral replication remains attractive as therapy, especially in combination with other treatments (like IFNa treatment and ribavirin in HCV patients). Furthermore, although TLR ligands and IFNs can induce production of restriction factors, these might also be applied directly to limit viral replication. On the other hand, IFN-inhibitor proteins of viruses can be targeted to restore immune functions [178] and make additional restriction factors or immunotherapy more effective.

Taken together, although viruses are well able to subvert or manipulate the type I IFN response, the IFN system can also be used or stimulated to strengthen the response towards viral infections. IFNs themselves are already used in HCV treatment, and promising effects have been shown in respiratory viral infections. Moreover, the therapeutic use of TLR ligands is currently under intense investigation as they have shown to have great potency to stimulate those immune cells critically involved in the antiviral immune response. This stimulates the production of antiviral proteins or inhibitors of viral evasion proteins, which can also be used independently of TLR stimulation or IFN application. Finally, the transfer of (stimulated) pDCs for gradual production of type I IFN and other cytokines (in combination with cDCs for induction of adaptive immunity) might be an option to limit symptoms or even control virus replication.

In the previous section, we revealed among others the opportunities related to TLR ligands as potential antiviral drugs. Yet, although promising results with TLR ligands have been reported during the last decade, there are also several threats.

Endosomal TLRs usually only respond to DNA/ RNA derived from pathogens while immune responses to host genetic material are prevented in different ways. First, DNA (and RNA) from apoptotic or necrotic host cells is removed by DNAses (and RNAses, respectively). Second, the nucleic acids from microbes are fundamentally different from host nucleic acids. Viral and bacterial DNA contain unmethylated CpG motifs, whereas in host DNA heavy methylation and fewer CpG motifs are common [179] . Furthermore, the TLRs that bind (microbial) nucleic acids are endosomally located [7, 14] . Because of this intracellular localization, self-nucleic acids cannot stimulate these TLRs. Finally, regulatory receptors are present on pDCs, which limit type I IFN responses [180] .

Sometimes, however, these barriers are not sufficient, and aberrant immune responses arise ultimately resulting in autoimmune diseases like systemic lupus erythematosus (SLE) [181] [182] [183] , an autoimmune disorder that especially affects the skin. In SLE, it is assumed that apoptotic or necrotic material containing nucleic acids are phagocytosed by pDCs and cDCs. The pDCs respond with production of type I IFN and other cytokines resulting in activation of the cDCs, which then stimulate autoreactive T and B cells. After differentiation of B cells into plasma cells, autoantibodies are produced and complex with the nucleic acids from necrotic cells. Subsequent binding to the Fc receptor for IgG (FcgRIIa) on pDCs [184] and cDCs results in further type I IFN production and B-cell stimulation [185] . This vicious cycle can be evoked or aggravated by the administration of TLR ligands. The reason why these pDCs respond to the hostderived nucleic acids is still unclear.

Thus, concerns about instigating or enhancing autoimmune diseases are important reason why TLR ligands are not extensively administered in the clinic. Despite promising results in the last decade with these ligands in antiviral therapy, precautionary measures to prevent induced autoimmune responses are definitely necessary.

Much of what we know comes from animal experiments, but translating experimental results from laboratory animals to humans is often problematic. This is also the case with the translation of our knowledge from the immune response of wellstudied mouse models to humans. For example, the response to certain viruses can be entirely different in both hosts, due to adaption of the virus to its host [186] . Moreover, important differences in antiviral mechanisms between mice and humans have been observed.

First, there are differences in the TLR-induced response. Studies indicate that murine pDCs are able to produce IL-12p70 in addition to IFNa post-TLR9 stimulation, whereas human pDCs do not [60,62,63]. Secondly, the location of TLR9 is different in mice than in humans. In humans, TLR9 is exclusively expressed in pDCs and B cells [187] while mice express TLR9 on cDCs, B-cells, macrophages, and monocytes [188] . Thus, a TLR9 ligand can induce entirely different responses in both species. Another major difference is the function of TLR8. TLR8 stimulation induces IL-12 production in humans [189] , but this receptor appears to be non-functional in mice, although this is still a matter of debate [190] . Finally, the cytokine flt-3 ligand is used to differentiate murine hematopoietic stem cells into DCs with a relatively high percentage of pDCs [191, 192] . This does not reflect the human situation in which most experiments are performed with PBMCs, containing a very low number of pDCs [154] [155] [156] 193] that are probably at a different stage of maturation.

Hence, as stimulation of the type I IFN response can improve immunity toward viral infection, it can also evoke or aggravate aberrant immune responses (autoimmunity), thereby limiting clinical application of TLR ligands and IFNs. Furthermore, although animal experiments have been extremely helpful in deciphering antiviral responses, these are not an exact representation of the human type I IFN response, further hindering clinical application.

In this review, we provided a condensed overview of the molecular pathways involved in the most potent antiviral part of the innate immune system, the type I IFN response. Moreover, we reviewed the cells and receptors that are intimately involved in this type I IFN system. Also, we evaluated the (im)possibilities of new ways to modulate the type I IFN response, for example, by TLR ligands or adoptive DC transfer, as promising future antiviral therapies. Nonetheless, although strong antiviral effects of IFNs, TLR ligands, DCs, and restriction factors have been shown by many studies, the clinical application of these immune-based therapies is unfortunately still limited, which might be related to concern for eventual undesired side effects like autoimmune diseases. Therefore, to be clinically successful, perhaps a more personalized approach is required. The application of these immune-based therapies can then be considered based on the individual, virus, stage of infection, and symptoms, thereby fine-tuning the type I IFN response and preventing side effects as much as possible.

The authors have no competing interest. 

HIV: a discovery opening the road to novel scientific knowledge and global health improvement

Global epidemiology of HIV

Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic

Emergence and pandemic potential of swineorigin H1N1 influenza virus

New respiratory viruses of humans

Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clinical 121

Activation of anti-hepatitis C virus responses via Toll-like receptor 7

Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes

Multiple effects of interferon on the replication of human immunodeficiency virus type 1

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebocontrolled trial

Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication

Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals

High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virustype 1 not associated with antitumor activity in subjects with Kaposi's sarcoma

Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity

A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits

Role of deficient type III interferon-lambda production in asthma exacerbations

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation

SARS: systematic review of treatment effects

Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

Interferon and cytokine responses to SARS-coronavirus infection

Human immunopathogenesis of severe acute respiratory syndrome (SARS)

Pathogenesis of severe acute respiratory syndrome. Current Opinion in

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo

Respiratory virus induction of alphabeta-and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections

Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells

Therapeutic potential of Tolllike receptor 9 activation

Clinical investigations of Toll-like receptor agonists

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

Translating innate immunity into immunological memory: implications for vaccine development

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells

Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection

Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis

Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Species-specific recognition of singlestranded RNA via toll-like receptor 7 and 8

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848)

Current and potential uses of imiquimod

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, doubleblind phase IIa studies

Phase 1B, randomized, double-blind, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus

Innate immunity and chronic immune activation in HCV/HIV-1 co-infection

Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific Tcell responses

Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients

Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans

Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection

The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus

Differential dysfunction in dendritic cell subsets during chronic HCV infection

Evidence of dysregulation of dendritic cells in primary HIV infection

Loss of blood CD11c(+) myeloid and CD11c(À) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load

Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy

Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection

Targeting signal transduction as a strategy to treat inflammatory diseases

Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense

CpG motifs in bacterial DNA and their immune effects

Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases

Type I interferon in systemic lupus erythematosus and other autoimmune diseases

Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

Fc gamma RIIa is expressed on natural IFN-alphaproducing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG

Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity

Use of functional genomics to understand influenzahost interactions

TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848)

A Toll-like receptor recognizes bacterial DNA

Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/ macrophage colony-stimulating factor

Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature

Viral induction of low frequency interferonalpha producing cells